CVE-2025-27720

Pixmeo OsiriX MD Cleartext Transmission of Sensitive Information

Description

The Pixmeo Osirix MD Web Portal sends credential information without encryption, which could allow an attacker to steal credentials.

Remediation

Solution:

  • Pixmeo recommends users to download the latest version of OsiriX MD https://www.osirix-viewer.com/osirix/osirix-md/ . For additional support regarding OsiriX MD, users should contact Pixmeo https://www.osirix-viewer.com/about/contact/  directly.

Category

9.3
CVSS
Severity: Critical
CVSS 4.0 •
CVSS 3.1 •
EPSS 0.01%
Affected: Pixmeo OsiriX MD
Published at:
Updated at:

References

Link Tags
https://www.cisa.gov/news-events/ics-medical-advisories/icsma-25-128-01
https://www.osirix-viewer.com/osirix/osirix-md/
https://www.osirix-viewer.com/about/contact/

Frequently Asked Questions

What is the severity of CVE-2025-27720?
CVE-2025-27720 has been scored as a critical severity vulnerability.
How to fix CVE-2025-27720?
To fix CVE-2025-27720: Pixmeo recommends users to download the latest version of OsiriX MD https://www.osirix-viewer.com/osirix/osirix-md/ . For additional support regarding OsiriX MD, users should contact Pixmeo https://www.osirix-viewer.com/about/contact/  directly.
Is CVE-2025-27720 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2025-27720 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2025-27720?
CVE-2025-27720 affects Pixmeo OsiriX MD.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.